[18F]DASA-23 and PET/MRI Scan in Evaluating Pyruvate Kinase M2 Expression in Patients with Intracranial Tumors or Recurrent Glioblastoma and Healthy Volunteers

Inclusion Criteria

• Age >= 18 years old
• Absolute neutrophil count (ANC) >= 1.5 X 10^9/L without (w/o) myeloid growth factor support for 7 days preceding lab assessment (obtained within 14 days prior to PET scan [Part 1, Part 2, and Part 3 only] or within 28 days prior to PET scan [Part 4 only])
• Hemoglobin (Hgb) >= 9 g/dL (90 g/L); < 9 g/dL (< 90 g/L) is acceptable if Hgb is corrected to >= 9 g/dL (90 g/L) as by growth factor or transfusion prior to PET scan (obtained within 14 days prior to PET scan [Part 1, Part 2, and Part 3 only] or within 28 days prior to PET scan [Part 4 only])
• Platelet count >= 100 X 10^9/L w/o blood transfusions for 7 days preceding lab assessment (obtained within 14 days prior to PET scan [Part 1, Part 2, and Part 3 only] or within 28 days prior to PET scan [Part 4 only])
• Bilirubin = < 1.5 X upper limit of normal (ULN) except for patients (pts) with (w/) documented history of Gilbert’s disease (obtained within 14 days prior to PET scan [Part 1, Part 2, and Part 3 only] or within 28 days prior to PET scan [Part 4 only])
• Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 X ULN (obtained within 14 days prior to PET scan [Part 1, Part 2, and Part 3 only] or within 28 days prior to PET scan [Part 4 only])
• Alkaline phosphatase (AP) =< 3 X ULN (obtained within 14 days prior to PET scan [Part 1, Part 2, and Part 3 ONLY] or within 28 days prior to PET scan [Part 4 ONLY])
• Women of childbearing potential (WCBP): negative serum pregnancy test (obtained within 14 days prior to PET scan [Part 1, Part 2, and Part 3 only] or within 28 days prior to PET scan [Part 4 only])
• Ability to stand up and climb two steps with minimal assistance
• Ability to understand and the willingness to sign a written informed consent document
• (Part 2, intracranial tumor patients only): Radiographical or pathological evidence of newly-diagnosed intracranial tumor that is status-pre surgical resection, or (b) Radiographical or pathological evidence of progressive/recurrent intracranial tumor, (c) Question of pseudoprogression vs. true progression on most recent standard-of-care brain magnetic resonance imaging (MRI), or (d) Evidence on the most recent standard-of-care brain MRI scan of intracranial metastasis/metastases in a patient with known extracranial primary cancer
• (Part 3, GBM patients only): Any patient with at least a 1cm^3 contrast-enhancing lesion suspicious for GBM (either newly-diagnosed or 1st /2nd/ 3rd recurrence of GBM, molecular GBM, diffuse astrocytomas with molecular features of GBM, H3K27M midline gliomas, gliosarcomas, or any other WHO Grade IV glioma) on a standard-of-care (SOC) brain MRI scan. If the patient undergoes a biopsy or resection for GBM (either newly-diagnosed or 1st /2nd/ 3rd recurrence of GBM, molecular GBM, diffuse astrocytomas with molecular features of GBM, H3K27M midline gliomas, gliosarcomas, or any other WHO Grade IV glioma) then the remaining contrast-enhancing lesion is at least 1cm^3 in size on the post-operative scan
• (Part 3, GBM patients only): Life expectancy of >= 6 months

Exclusion Criteria

• Known allergy to adhesive tapes or other skin adhesives used in medical care
• Known cirrhosis diagnosed with Child Pugh class A or higher liver disease
• Severe/uncontrolled inter current illness within the previous 28 days prior to PET scan
• Patients who have implantable devices that are contraindicated for MRI
• Bleeding disorder
• Any other significant co morbid conditions that in the opinion of the investigator would impair study participation or cooperation
• EXCLUSION - HEALTHY VOLUNTEERS: Prior or current malignancy (Part 1 and Part 4 only)
• EXCLUSION - HEALTHY VOLUNTEERS: Known kidney disease (Part 1 and Part 4 only)
• Pregnant or nursing participants
• History of allergic reactions to gadolinium-based MRI contrast agent
• (Part 2, intracranial tumor patients only): Other chemotherapy (besides what is being used to treat the intracranial tumor)
• (Part 3, GBM patients only): Having received therapy (e.g., radiation, chemotherapy) within 5 days prior to the first of two [18F]DASA 23 PET/MRI scans